Seelos Therapeutics, Inc. (SEEL) News

Seelos Therapeutics, Inc. (SEEL): $1.03

0.03 (+2.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SEEL to Watchlist
Sign Up

Industry: Biotech


Ranked

of 379

in industry

Filter SEEL News Items

SEEL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SEEL News Highlights

  • SEEL's 30 day story count now stands at 2.
  • Over the past 16 days, the trend for SEEL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • RARE are the most mentioned tickers in articles about SEEL.

Latest SEEL News From Around the Web

Below are the latest news stories about SEELOS THERAPEUTICS INC that investors may wish to consider to help them evaluate SEEL as an investment opportunity.

Seelos Therapeutics to Hold a Research and Development Update Conference Call and Webcast on December 15, 2022

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will hold a research and development update conference call and webcast on Thursday, December 15th from 1pm to 3pm ET.

Yahoo | November 23, 2022

Seelos Therapeutics to Participate in the Guggenheim 4th Annual Immunology and Neurology Day

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Guggenheim 4th Annual Immunology and Neurology Day, November 14th and 15th.

Yahoo | November 7, 2022

10 Penny Stocks To Buy That Are Too Cheap To Ignore

In this piece, we will take a look at the top ten penny stocks that are too cheap to ignore. For more stocks, head on over to 5 Penny Stocks To Buy That Are Too Cheap To Ignore. Out of the thousands of stocks that are traded on public markets and are available to retail […]

Yahoo | November 1, 2022

7 Speculative Penny Stocks Under $3 That Deserve Your Attention in Nov.

Speculative penny stocks don't look as volatile now that volatility is unavoidable.

Alex Sirois on InvestorPlace | October 28, 2022

Seelos Therapeutics to Sponsor and Participate in Wonderland, the World's Leading Psychedelic Event

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it will sponsor and participate in Wonderland, the World's Leading Psychedelic Event, organized by Microdose Psychedelics Insights, to be held at the Mana Wynwood Convention Center in Miami, FL from November 3rd to the 5th.

Yahoo | October 27, 2022

Seelos Therapeutics Doses First Patient in a Registrational Phase II/III study of SLS-005 in Spinocerebellar Ataxia

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced dosing of the first patient in a registrational phase II/III study of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of spinocerebellar ataxia focusing on participants with type3 (SCA3, also known as Machado-Joseph disease) and also announced that it will participa

Yahoo | October 25, 2022

4 Out Of 5 Cannabis Category Indexes Improved Last Week

All four of our cannabis-related indexes were up last week, while only the partly-related Psychedelic Compounds index dropped again.

TalkMarkets.com | October 24, 2022

Seelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program Funded by a Grant from the National Institute of Neurological Disorders and Stroke under the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS)

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it will collaborate with the Sean M. Healey & AMG Center for ALS in an Expanded Access Program (EAP) that will be fully funded by a grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the ACT for ALS.

Yahoo | September 30, 2022

Seelos Therapeutics Announces the Participation of Acadia Healthcare in the Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the participation of Acadia Healthcare Company, Inc. (Nasdaq: ACHC) in the registration directed Proof of Concept study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD).

Yahoo | September 13, 2022

Seelos Therapeutics to Participate in the Guggenheim Nantucket Therapeutics Conference

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Guggenheim Nantucket Therapeutics Conference, September 27th to 29th.

Yahoo | September 9, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6706 seconds.